MedTrace Logo

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation

NCT00408200 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2013-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the overall effectiveness of anti-arrhythmic medicines (to control heart rhythm) prescribed after an ablation procedure for atrial fibrillation.

Conditions

Interventions

DRUG

propafenone; flecainide; sotalol; dofetilide

Above drugs prescribed per established guidelines for treatment of AF

DEVICE

Radiofrequency catheter ablation

A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.

Sponsors & Collaborators

Principal Investigators

  • Edward P. Gerstenfeld, MD · University of Pennsylvania Health System - Cardiac Electrophysiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-04-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408200 on ClinicalTrials.gov